SRPK1 and Familial prostate cancer: Both the knockdown and pharmacological inhibition of SRPK1 shifts the ratio of splice isoforms in favour of the anti-angiogenic isoform of VEGFA165b (24), and we have proposed that targeting SRPK1 could be a viable avenue in prostate cancer (25).